The DOI matches its Crossref record.
The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors
Abstract
In Brief Objective: To evaluate the impact of 68Ga-DOTATOC positron emission tomography (PET)/computed tomography (CT) on the multimodal management of neuroendocrine tumors (NET). Background: Establishment of the extent and progression of NET are necessary to decide which treatment option to choose. However, morphological imaging with CT or magnetic resonance imaging (MRI) is often inadequate in identifying the primary tumor and/or in detecting small metastatic lesions. Methods: In total, 52 patients (27 women and 25 men) with histologically proven NET could be included in the protocol of comparison between 68Ga-DOTATOC PET/CT and CT and/or MRI. The examinations were performed in terms of tumor staging and, in some instances, also of primary tumor site identification to evaluate the patient's eligibility for treatment. Each patient presented with either CT and/or MRI performed elsewhere and consecutively underwent 68Ga-DOTATOC PET/CT in our institution. Results: In all 52 patients, 68Ga-DOTATOC PET/CT demonstrated pathologically increased uptake for at least 1 tumor site, yielding a sensitivity of 100% on a patient basis. In 3 of 4 patients with unknown primary tumor site, 68Ga-DOTATOC PET/CT visualized the primary tumor region (jejunum, ileum, and pancreas, respectively) not identified on CT and/or MRI. 68Ga-DOTATOC PET/CT detected additional hepatic and/or extrahepatic metastases in 22 of the 33 patients diagnosed with hepatic metastases on CT and/or MRI. Of the 15 patients evaluated for liver transplantation, we omitted 7 (46.6%) from further screening because of evidence of metastatic deposits not seen by conventional imaging. Overall, 68Ga-DOTATOC PET/CT altered our treatment decision based on CT and/or MRI alone, in 31 (59.6%) of the 52 patients. Conclusions: In this study, 68Ga-DOTATOC PET/CT proved clearly superior to CT and/or MRI for detection and staging of NET. More important, 68Ga-DOTATOC PET/CT impacted our treatment decision in more than every second patient. This study evaluated the impact of 68Ga-DOTATOC PET/CT on the multimodal management of 52 patients with advanced neuroendocrine tumors. Overall, 68Ga-DOTATOC PET/CT altered our treatment decision based on standard imaging alone, in 59.6% of patients. This imaging modality has the potential to optimize the management of patients with neuroendocrine tumors and to improve the outcome of surgical treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Falconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Hofman, M. S., Lau, W. F. E., & Hicks, R. J. (2015) · RadioGraphics · doi:10.1148/rg.352140164 · Cited by 561
Recommendations for management of patients with neuroendocrine liver metastases
Frilling, A., Modlin, I. M., Kidd, M., Russell, C., Breitenstein, S., Salem, R., Kwekkeboom, D., Lau, W.-Y., Klersy, C., Vilgrain, V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70362-0 · Cited by 527
Self-citationSundin, A., Arnold, R., Baudin, E., Cwikla, J. B., Eriksson, B., Fanti, S., Fazio, N., Giammarile, F., Hicks, R. J., Kjaer, A., et al. (2017) · Neuroendocrinology · doi:10.1159/000471879 · Cited by 501
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202275 · Cited by 363
Metadata
- Authors
- Frilling, A., Sotiropoulos, G. C., Radtke, A., Malago, M., Bockisch, A., Kuehl, H., Li, J., & Broelsch, C. E.
- Venue
- Annals of Surgery
- Published
- 2010-11
- Volume
- 252
- Issue
- 5
- Pages
- 850-856
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2061345028
- Cited by
- 222
- References
- 0
- FWCI
- 7.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors. https://app.cochat.ai/papers/10.1097/sla.0b013e3181fd37e8
- The paper
- Frilling, A., Sotiropoulos, G. C., Radtke, A., Malago, M., Bockisch, A., Kuehl, H., Li, J., & Broelsch, C. E. (2010). The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors. Annals of Surgery. https://doi.org/10.1097/sla.0b013e3181fd37e8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.